95 results
6-K
EX-99.1
ALVO
Alvotech
21 May 24
Current report (foreign)
9:00am
biosimilars and new presentations of two previously partnered products. Alvotech handles development and manufacturing, while Teva is responsible
6-K
EX-99.1
ALVO
Alvotech
21 May 24
Current report (foreign)
8:41am
in Europe and United Kingdom (UK)
Alvotech will be responsible for development and manufacture of the product
HYDERABAD, India and REYKJAVIK, Iceland, May 21 … events in adults with advanced malignancies*.
Alvotech will be responsible for development and manufacturing of the product. Dr. Reddy’s
6-K
EX-99.1
ALVO
Alvotech
30 Apr 24
Current report (foreign)
8:00am
additional biosimilars and two new presentations of previously partnered products. Alvotech handles development and manufacturing, and Teva is responsible
6-K
EX-99.1
ALVO
Alvotech
16 Apr 24
Current report (foreign)
6:30pm
between Teva and Alvotech, Teva is responsible for the exclusive commercialization of SELARSDI in the United States.
“The approval of SELARSDI – which … is responsible for the exclusive commercialization in the U.S., which leverages Teva’s experience and extensive sales and marketing infrastructure. SELARSDI
6-K
EX-99.3
ims3ofsi
20 Mar 24
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
4:30pm
6-K
EX-99.2
fpxyy 4ho5257trev
20 Mar 24
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
4:30pm
6-K
EX-99.1
73y1bmz5
23 Feb 24
Current report (foreign)
8:39pm
6-K
EX-99.1
ceht2vh 40hsp60lqc1m
10 Jan 24
STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara
7:00am
6-K
EX-99.1
agxgy9e6
13 Nov 23
STADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to Stelara
6:15am
UPLOAD
1ky33z4cpmxczeg59fyk
26 Oct 23
Letter from SEC
12:00am
F-3
8pisq98suc9zv6lvu1
20 Oct 23
Shelf registration (foreign)
4:06pm
F-3
EX-4.5
w54whs6 0d
20 Oct 23
Shelf registration (foreign)
4:06pm
424B3
82bju evy
24 Jul 23
Prospectus supplement
8:03am
424B3
bfllfif3s
24 Jul 23
Prospectus supplement
8:00am
UPLOAD
hqvoawtc4bqxvft
20 Jul 23
Letter from SEC
12:00am
F-3
m6xh6 dl4t
14 Jul 23
Shelf registration (foreign)
4:56pm
POS AM
071 y4fppwkgwb
14 Jul 23
Prospectus update (post-effective amendment)
4:45pm